Free Trial
NASDAQ:ERNA

Eterna Therapeutics (ERNA) Stock Price, News & Analysis

Eterna Therapeutics logo
$0.17 -0.05 (-22.93%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$0.18 +0.01 (+3.21%)
As of 03/28/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Eterna Therapeutics Stock (NASDAQ:ERNA)

Key Stats

Today's Range
$0.16
$0.25
50-Day Range
$0.17
$0.64
52-Week Range
$0.16
$2.63
Volume
923,050 shs
Average Volume
2.78 million shs
Market Capitalization
$943,678.40
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Remove Ads

Eterna Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

ERNA MarketRank™: 

Eterna Therapeutics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Eterna Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eterna Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eterna Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eterna Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Eterna Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    1.88% of the float of Eterna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Eterna Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eterna Therapeutics has recently increased by 6.03%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Eterna Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Eterna Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.88% of the float of Eterna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Eterna Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eterna Therapeutics has recently increased by 6.03%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Eterna Therapeutics has a news sentiment score of 0.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.81 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Eterna Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for ERNA on MarketBeat in the last 30 days.
  • MarketBeat Follows

    1 people have added Eterna Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eterna Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.49% of the stock of Eterna Therapeutics is held by insiders.

  • Percentage Held by Institutions

    70.55% of the stock of Eterna Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eterna Therapeutics' insider trading history.
Receive ERNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eterna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ERNA Stock News Headlines

Eterna changes name to Ernexa Therapeutics
A brutally honest economic warning for 2025 (see proof)
New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....
Eterna hosts inaugural meeting of newly formed SAB
Eterna appoints Zeldis, Sather to scientific advisory board
See More Headlines

ERNA Stock Analysis - Frequently Asked Questions

Eterna Therapeutics' stock was trading at $0.2940 at the beginning of the year. Since then, ERNA stock has decreased by 40.7% and is now trading at $0.1744.
View the best growth stocks for 2025 here
.

Eterna Therapeutics Inc. (NASDAQ:ERNA) issued its earnings results on Tuesday, November, 12th. The company reported ($4.92) EPS for the quarter. The business earned $0.49 million during the quarter.

Eterna Therapeutics' top institutional shareholders include Geode Capital Management LLC (4.76%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include John D Halpern and Nicholas Jason Singer.
View institutional ownership trends
.

Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eterna Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Inuvo (INUV).

Company Calendar

Last Earnings
11/12/2024
Today
3/30/2025
Next Earnings (Estimated)
5/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ERNA
Employees
10
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,670,000.00
Net Margins
-7,513.88%
Pretax Margin
-7,511.37%

Debt

Sales & Book Value

Annual Sales
$582,000.00
Price / Cash Flow
N/A
Book Value
$0.41 per share
Price / Book
0.43

Miscellaneous

Free Float
5,168,000
Market Cap
$943,678.40
Optionable
No Data
Beta
4.47
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:ERNA) was last updated on 3/31/2025 by MarketBeat.com Staff
From Our Partners